HC Wainwright Issues Negative Estimate for BHST Earnings

BioHarvest Sciences Inc. (NASDAQ:BHST) – Equities researchers at HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for BioHarvest Sciences in a report released on Thursday, April 23rd. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings of ($0.11) per share for the quarter, down from their prior forecast of ($0.04). The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.35) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.25) EPS.

A number of other equities research analysts have also recently issued reports on BHST. Roth Mkm began coverage on BioHarvest Sciences in a report on Thursday, February 19th. They set a “buy” rating and a $10.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of BioHarvest Sciences in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $12.50.

BioHarvest Sciences Stock Performance

Shares of NASDAQ:BHST opened at $4.38 on Monday. BioHarvest Sciences has a 12-month low of $4.10 and a 12-month high of $12.80. The stock has a market cap of $85.94 million, a PE ratio of -7.18 and a beta of 1.16. The business has a 50 day moving average of $4.38 and a 200-day moving average of $5.93. The company has a quick ratio of 3.38, a current ratio of 3.97 and a debt-to-equity ratio of 0.10.

Institutional Investors Weigh In On BioHarvest Sciences

Several institutional investors have recently made changes to their positions in BHST. Alyeska Investment Group L.P. bought a new stake in shares of BioHarvest Sciences in the fourth quarter valued at approximately $3,929,000. Thompson Siegel & Walmsley LLC bought a new stake in shares of BioHarvest Sciences in the fourth quarter valued at approximately $1,945,000. Evercore Wealth Management LLC bought a new stake in shares of BioHarvest Sciences in the fourth quarter valued at approximately $724,000. King Luther Capital Management Corp bought a new stake in shares of BioHarvest Sciences in the fourth quarter valued at approximately $208,000. Finally, Osaic Holdings Inc. boosted its stake in shares of BioHarvest Sciences by 5,510.4% in the fourth quarter. Osaic Holdings Inc. now owns 35,233 shares of the company’s stock valued at $183,000 after buying an additional 34,605 shares during the period.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.